Privia Health Group (NASDAQ:PRVA) Price Target Lowered to $19.00 at Barclays
The Cerbat Gem -

Privia Health Group (NASDAQ:PRVA – Free Report) had its target price lowered by Barclays from $22.00 to $19.00 in a research report sent to investors on Monday morning, Benzinga reports. Barclays currently has an equal weight rating on the stock. A number of other research analysts have also weighed in on the stock. TD Cowen […]

In related news